Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
KRAS G12V
|
colorectal cancer
|
sensitive |
Regorafenib + Cetuximab
|
Preclinical |
Actionable |
In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G12V in culture (PMID: 25838391).
|
25838391
|
KRAS G13D
|
colorectal cancer
|
sensitive |
Regorafenib + Cetuximab
|
Preclinical |
Actionable |
In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis in human colorectal cancer cell lines harboring KRAS G13D in culture (PMID: 25838391).
|
25838391
|
Unknown unknown
|
Advanced Solid Tumor
|
not applicable |
Regorafenib + Cetuximab
|
Phase I |
Actionable |
In a Phase I trial, the combination of Stivarga (regorafenib) and Erbitux (cetuximab) resulted in a clinical benefit of either stable disease or partial response in 46% (11/24) of advanced solid tumor patients, including eight patients with colorectal cancer, and one patient with head and neck cancer, one with carcinoma of unknown primary, and one with glioblastoma (PMID: 28422758; NCT02095054).
|
28422758
|